EUCTR2020-003645-11-GR进行中（未招募）1 期
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- •Candidacy to receive treatment with docetaxel.
- •Crossover inclusion criteria
- •1. Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- •2. EGOG performance status 0-2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, sotorasib).
- •Active brain metastases.
- •Crossover Exclusion Criteria:
- •1. Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study
研究者
相似试验
招募中
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-NLMirati Therapeutics, Inc.450
招募中
3 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationAdvanced Non-Small Cell Lung Cancer2023-507263-19-00Mirati Therapeutics Inc.557
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-CZMirati Therapeutics, Inc.450
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-IEMirati Therapeutics, Inc.450
进行中（未招募）
1 期
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutatioAdvanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003645-11-PLMirati Therapeutics, Inc.450